Name | Number of supported studies | Average coverage | |
---|---|---|---|
macrophage | 40 studies | 45% ± 18% | |
microglial cell | 15 studies | 61% ± 18% | |
endothelial cell of lymphatic vessel | 13 studies | 28% ± 10% | |
myeloid cell | 13 studies | 40% ± 16% | |
endothelial cell | 11 studies | 40% ± 15% | |
mast cell | 10 studies | 36% ± 20% | |
alveolar macrophage | 8 studies | 46% ± 14% | |
monocyte | 5 studies | 28% ± 11% | |
dendritic cell | 5 studies | 24% ± 13% | |
hepatocyte | 5 studies | 47% ± 17% | |
mononuclear phagocyte | 4 studies | 35% ± 11% | |
tissue-resident macrophage | 3 studies | 53% ± 9% |
Name | Number of supported studies | Average coverage | |
---|---|---|---|
brain | 4 studies | 30% ± 19% |
Tissue | GTEx Coverage | GTEx Average TPM | GTEx Number of samples | TCGA Coverage | TCGA Average TPM | TCGA Number of samples |
---|---|---|---|---|---|---|
brain | 96% | 3565.78 | 2549 / 2642 | 100% | 55.77 | 703 / 705 |
liver | 100% | 17003.70 | 226 / 226 | 93% | 48.07 | 379 / 406 |
intestine | 99% | 4585.74 | 955 / 966 | 91% | 19.81 | 480 / 527 |
lung | 100% | 9574.04 | 578 / 578 | 86% | 23.35 | 997 / 1155 |
breast | 98% | 3654.34 | 451 / 459 | 86% | 15.63 | 959 / 1118 |
thymus | 98% | 3188.40 | 641 / 653 | 78% | 10.78 | 473 / 605 |
pancreas | 88% | 1872.20 | 290 / 328 | 87% | 20.80 | 155 / 178 |
stomach | 72% | 1384.68 | 257 / 359 | 96% | 23.00 | 274 / 286 |
kidney | 82% | 2423.92 | 73 / 89 | 85% | 26.84 | 768 / 901 |
esophagus | 95% | 2571.43 | 1379 / 1445 | 68% | 11.51 | 124 / 183 |
bladder | 100% | 3092.00 | 21 / 21 | 59% | 12.29 | 299 / 504 |
adrenal gland | 100% | 6755.41 | 257 / 258 | 51% | 6.64 | 117 / 230 |
prostate | 92% | 2037.49 | 225 / 245 | 50% | 4.90 | 251 / 502 |
uterus | 95% | 2483.71 | 162 / 170 | 45% | 5.95 | 207 / 459 |
ovary | 75% | 1637.85 | 135 / 180 | 63% | 10.18 | 271 / 430 |
skin | 43% | 685.98 | 779 / 1809 | 71% | 14.22 | 333 / 472 |
adipose | 99% | 5933.42 | 1189 / 1204 | 0% | 0 | 0 / 0 |
spleen | 98% | 10261.34 | 236 / 241 | 0% | 0 | 0 / 0 |
lymph node | 0% | 0 | 0 / 0 | 93% | 27.94 | 27 / 29 |
heart | 86% | 1740.39 | 741 / 861 | 0% | 0 | 0 / 0 |
blood vessel | 82% | 3058.47 | 1101 / 1335 | 0% | 0 | 0 / 0 |
tonsil | 0% | 0 | 0 / 0 | 67% | 12.40 | 30 / 45 |
eye | 0% | 0 | 0 / 0 | 28% | 2.88 | 22 / 80 |
muscle | 18% | 219.82 | 142 / 803 | 0% | 0 | 0 / 0 |
peripheral blood | 5% | 89.84 | 44 / 929 | 0% | 0 | 0 / 0 |
abdomen | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
bone marrow | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
diaphragm | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
gingiva | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
nasal cavity | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
nasopharynx | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
nose | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
placenta | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
spinal column | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
ureter | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 1 |
GO_0015721 | Biological process | bile acid and bile salt transport |
GO_0006811 | Biological process | monoatomic ion transport |
GO_0043252 | Biological process | sodium-independent organic anion transport |
GO_0006805 | Biological process | xenobiotic metabolic process |
GO_0015732 | Biological process | prostaglandin transport |
GO_0042167 | Biological process | heme catabolic process |
GO_0015711 | Biological process | organic anion transport |
GO_0055085 | Biological process | transmembrane transport |
GO_0150104 | Biological process | transport across blood-brain barrier |
GO_0016324 | Cellular component | apical plasma membrane |
GO_0009925 | Cellular component | basal plasma membrane |
GO_0005886 | Cellular component | plasma membrane |
GO_0016323 | Cellular component | basolateral plasma membrane |
GO_0015132 | Molecular function | prostaglandin transmembrane transporter activity |
GO_0015125 | Molecular function | bile acid transmembrane transporter activity |
GO_0008514 | Molecular function | organic anion transmembrane transporter activity |
GO_0015347 | Molecular function | sodium-independent organic anion transmembrane transporter activity |
GO_0022857 | Molecular function | transmembrane transporter activity |
Gene name | SLCO2B1 |
Protein name | Solute carrier organic anion transporter family member 2B1 Solute carrier organic anion transporter family member 2B1 (Organic anion transporter B) (OATP-B) (Organic anion transporter polypeptide-related protein 2) (OATP-RP2) (OATPRP2) (Organic anion transporting polypeptide 2B1) (OATP2B1) (Solute carrier family 21 member 9) Solute carrier organic anion transporter family, member 2B1 Solute carrier organic anion transporter family member |
Synonyms | OATP2B1 KIAA0880 OATPB SLC21A9 |
Description | FUNCTION: Mediates the Na(+)-independent transport of steroid sulfate conjugates and other specific organic anions . Responsible for the transport of estrone 3-sulfate (E1S) through the basal membrane of syncytiotrophoblast, highlighting a potential role in the placental absorption of fetal-derived sulfated steroids including the steroid hormone precursor dehydroepiandrosterone sulfate (DHEA-S) . Also facilitates the uptake of sulfated steroids at the basal/sinusoidal membrane of hepatocytes, therefore accounting for the major part of organic anions clearance of liver . Mediates the intestinal uptake of sulfated steroids . Mediates the uptake of the neurosteroids DHEA-S and pregnenolone sulfate (PregS) into the endothelial cells of the blood-brain barrier as the first step to enter the brain . Also plays a role in the reuptake of neuropeptides such as substance P/TAC1 and vasoactive intestinal peptide/VIP released from retinal neurons . May act as a heme transporter that promotes cellular iron availability via heme oxygenase/HMOX2 and independently of TFRC . Also transports heme by-product coproporphyrin III (CPIII), and may be involved in their hepatic disposition . Mediates the uptake of other substrates such as prostaglandins D2 (PGD2), E1 (PGE1) and E2 (PGE2), taurocholate, L-thyroxine, leukotriene C4 and thromboxane B2 . May contribute to regulate the transport of organic compounds in testis across the blood-testis-barrier (Probable). Shows a pH-sensitive substrate specificity which may be ascribed to the protonation state of the binding site and leads to a stimulation of substrate transport in an acidic microenvironment . The exact transport mechanism has not been yet deciphered but most likely involves an anion exchange, coupling the cellular uptake of organic substrate with the efflux of an anionic compound . Hydrogencarbonate/HCO3(-) acts as a probable counteranion that exchanges for organic anions . Cytoplasmic glutamate may also act as counteranion in the placenta . An inwardly directed proton gradient has also been proposed as the driving force of E1S uptake with a (H(+):E1S) stoichiometry of (1:1) . .; FUNCTION: [Isoform 3]: Has estrone 3-sulfate (E1S) transport activity comparable with the full-length isoform 1. . |
Accessions | E9PIU9 E9PRW4 ENST00000525845.5 ENST00000526839.1 E9PN87 ENST00000534186.5 ENST00000532236.5 C7BWB7 O94956 A0A1B0GX35 ENST00000534004.5 C7BWB6 ENST00000531713.5 A0A0A0MTF1 E9PI53 H0YE11 ENST00000428359.6 [O94956-3] ENST00000525650.5 [O94956-4] ENST00000527180.5 ENST00000525650.5 ENST00000289575.10 [O94956-1] ENST00000454962.6 [O94956-2] ENST00000530556.5 |